Proteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian Cancer Cell Lines
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073035 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Mahfuza Marzan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA. Hauptthemen laut MEDLINE: Leupeptins, Tumor Suppressor Protein p53, Apoptosis, Ovarian Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Margaret Ewell Dickens Family Foundation, Celma Mastry Foundation.
Abstract (Originalsprache)
Ovarian cancer is the most lethal gynecological cancer, with a 5-year survival rate of approximately 50%. Mutation in the p53 gene and overexpression of the atypical protein kinase C iota (PKC-ι) are two phenomena widely manifested in ovarian cancer. This study investigated the role of PKC-ι-specific inhibitor ICA-1S and proteasome inhibitor MG-132 in ovarian cancer cell lines. To discern the result, cell proliferation assays, cytotoxicity assays, Western blotting, immunofluorescence, flow cytometry, small interfering RNA, and co-immunoprecipitation techniques were applied. ICA-1S and MG-132 were found to inhibit the proliferation of ovarian cancer cell lines significantly. ICA-1S reduced the level of oncogenic PKC-ι as expected. In addition, ICA-1S and MG-132 both were able to decrease the level of mutated p53 in the ES-2 cell line through separate pathways. On the contrary, MG-132 increased the level of wild-type p53 in the HEY-T30 cell line by inhibiting proteasomal degradation. MG-132 also induced apoptosis and autophagy in the ovarian cancer cell lines. We concluded that ICA-1S alone or in combination with MG-132 could be a potential treatment for mutated p53-containing and PKC-ι-overexpressing ovarian cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA.
ORCID-Profile: Abigail Oluwafisayo Olatunji, Abiral Hasib Shourav, Aaron Joshua Astalos, James W Leahy
Förderung
- Margaret Ewell Dickens Family Foundation
- Celma Mastry Foundation
Zitieren
APA
Marzan, M., Nowshin Oishee, N., Olatunji, A. O., Hasib Shourav, A., Noor, R. E., Astalos, A. J., Leahy, J. W., & Acevedo-Duncan, M. (2025). Proteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian Cancer Cell Lines. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073035
Vancouver
Marzan M, Nowshin Oishee N, Olatunji AO, Hasib Shourav A, Noor RE, Astalos AJ, et al. Proteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian Cancer Cell Lines. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073035
BibTeX
@article{Marzan2025,
author = {Marzan, Mahfuza and Nowshin Oishee, Nuzhat and Olatunji, Abigail Oluwafisayo and Hasib Shourav, Abiral and Noor, Radwan Ebna and Astalos, Aaron Joshua and Leahy, James W and Acevedo-Duncan, Mildred},
title = {Proteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian Cancer Cell Lines},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073035}
}
EUVIMED